● 关注医药合作的年度品牌盛会，深度聚焦药企创新出海新机遇

● 特设新药出海与跨境合作、产品创新与商业模式专场，洞察医药合作新风向

● 更有投融资与项目估值、BD交易实战演练、路演专场，BD交易过程深度剖析

● 80+众多医药领袖，650+行业同仁, 积极寻求合作新机遇与新趋势！

● The annual brand conference focusing on pharmaceutical cooperation, with a deep focus on new opportunities for pharmaceutical companies to innovate and global

● Special sessions on new drugs going abroad and cross-border cooperation, product innovation and business models, gain insight into the new trend of pharmaceutical cooperation

● Special sessions on investment and financing, project valuation, BD transaction workshop and roadshow, and in-depth analysis of BD transaction process

● 80+ pharmaceutical leaders, 650+ industry colleagues, actively seeking new opportunities and trends in cooperation!

论坛基本形式

Basic Format For Summit

本次大会第二日特设“MNC+Pharma”和“Global Biotech”两个主题路演专场，超20场路演席位火热征集中，将邀请在某个领域获得突破性进展并在寻求合作、投资机会的企业参与。

此次路演旨在加强企业间的交流与合作，将是企业展现优势项目、寻找合作伙伴的绝佳舞台。

更多赞助、演讲等合作细节欢迎详询洽谈！

On the second day of the conference, there will be two roadshow sessions, "MNC+Pharma" and "Global Biotech", and over 20 roadshow sessions will be held to invite companies that have made breakthroughs in a certain field and are looking for cooperation and investment opportunities.

The roadshow aims to strengthen the communication and cooperation between enterprises, and will be an excellent stage for enterprises to showcase their advantageous projects and find partners.

For more details on sponsorship, speeches and other cooperation, please contact us to discuss.

【招商火热进行中，扫码立即咨询】

Aili Li

T：(86 21) 6095 7201

M：138 4991 9680

E：aili.li@shine-consultant.com

部分确认发言嘉宾（中英文）

Confirmed Session Speakers（CN & EN）

杨建新博士

Jianxin YANG

首席执行官，执行董事/

CEO & Executive Director

基石药业/CStone Pharmaceuticals

临床医学专家、科学家，拥有海外大型跨国药企、科研院所等机构逾25年的学术科研及生物制药研发的资深经验，涵盖从药物发现, 转化医学到临床开发阶段。发表文章/会议报告50余篇，拥有专利9项；

现任基石药业首席执行官以及执行董事，全面负责基石各项业务发展以及策略制定；六年时间里带领基石药业成功上市四款创新药，分别为泰吉华®（阿伐替尼），普吉华®（普拉替尼），择捷美®（舒格利单抗），拓舒沃®（艾伏尼布）；曾任百济神州高级副总裁及临床开发负责人；组建百济神州临床团队，并领导4个肿瘤药物从一期到关键试验阶段的临床开发工作，包括已获批上市的中国首个自主研发的抗PD-1替雷利珠单抗，BTK抑制剂泽布替尼和PARP抑制剂帕米帕利；曾任美国科文斯肿瘤医学总监；曾任辉瑞肿瘤生物标记物资深首席科学家；曾任Tularik/Amgen公司研究科学家; 领导超过十个肿瘤项目的研究与开发；拥有美国德州西南医学院博士学位，师从诺贝尔奖获得者Mike Brown博士和Joseph Goldstein博士；哈佛大学博士后，师从Stuart Schreiber博士；此前在南京医科大学和湖北医学院咸宁分院取得医学学位。

陈力博士

Li CHEN

首席执行官/CEO

华领医药/Hua Medicine (Shanghai) Ltd.

陈力博士，华领医药创始人、董事长、首席执行官兼首席科学官，建立了全球第一家实现血糖传感器葡萄糖激酶激活剂(GKA)临床开发的公司，实现了糖尿病新药多格列艾汀全球首创、中国首发。在他的带领下，华领医药成功完成了两项53周III期注册临床研究，并于2021年获NMPA受理NDA申请。在此期间，成功完成2亿美元融资，并与拜耳和国药集团建立了商业化合作伙伴关系。

陈力博士1992年毕业于爱荷华州立大学，获博士学位，同年加入罗氏美国研发中心，从一名药物化学资深研究员成长为高通量技术部主任，2004年回国建立罗氏中国研发中心，任首席科学官和董事。陈力博士是80件授权发明专利和212件发明专利申请的发明人，并发表近70篇科学论文（截止2022年8月）。

Dr. Li Chen, Founder, Executive Director, Chief Executive Officer, and Chief Scientific Officer, leads Hua Medicine a clinical stage biotech company whose mission is to bring disease modifying diabetes medicines to patients in China and worldwide. Hua Medicine leverages global resources to develop a first-in-class GKA dorzagliatin for diabetes. Under his leadership, Hua Medicine successfully completed registration trial, filed China NDA and demonstrated diabetes remission induced by dorzagliatin. During this period, Hua Medicine raised 200M USD and established commercialization partnership with Bayer and Sionpharm for dorzagliatin.

Li received his PhD at Iowa State University and joined Roche R&D center in USA in 1992. With 18 years at Roche, Li advanced his career from a medicinal chemist to the head of High Throughput Technology, and later CSO of Roche China R&D Center with a membership at Roche Research Leadership Team. He is an inventor of 80 granted patents, 212 patent applications and an author with about 70 publications (Until August 2022).

崔海峰博士

Haifeng CUI

研发总经理/CSO

济民可信/Jemincare

崔海峰毕业于浙江大学高分子化学专业，后参加工作任助理工程师，在浙江省化工研究院从事高分子材料研发工作，期间一成果获国家科学进步二等奖。 1997年进入美国宾西法尼亚大学深造，于2002年获有机化学博士。2002年起加入位于美国费城都会区的英国大型制药公司GSK从事原创新药研发，历任资深科学家，研究员，主任科学家至科学总监，先后领导过十余个新药项目，覆盖靶点发现到临床PoC全流程，目前有四个项目进入临床，其中一个进入临床三期。主要疾病领域在心血管，传染病，免疫及肿瘤。2019年10月回到中国，加入J&J亚太创新中心任资深总监，负责在亚太地区打造新药研发的生态圈，以及寻求与当地创新公司和科研院所的合作机会，疾病领域包括传染病及疫苗，神经科学，心血管及代谢，和免疫。2021年3月加入济民可信，负责整体的研发工作。

PhD in organic chemistry from University of Pennsylvania. Started his drug discovery career at GSK from 2002 in the USA, worked across several therapeutic areas including cardiovascular, renal disease and infectious disease, over the years led multi-discipline teams delivered several compounds into clinic and follow-up to human PoC. From 2019, he returned to China and jointed J&J, performing search and evaluation for opportunities up to phase 2a to feed into global pipeline, covering infectious disease & vaccine, immunology, neuroscience, cardiovascular & metabolic diseases in the APAC region. Currently he leads the R&D organization of Jemincare Group, advancing an extensive portfolio of innovative medicines into clinical practice.

陈晨博士

Michael CHEN

业务发展副总裁/BD VP

先声药业/Simcere Pharmaceutical

陈晨 (Michael) 博士，现担任江苏先声药业副总裁，主要负责领导公司业务发展和联盟管理中国团队的工作。

在加入先声之前，陈博士曾担任中山康方BD副总裁，和德国默克公司医药研发外部创新亚太区负责。在默克工作期间，陈博士是默克亚洲和中国研发中心的领导成员之一，针对自身研发管线，协助团队开展亚太地区的协同工作，并管理亚太地区以建立起来的研发创新外部合作。

归国前，陈博士先后在英国埃塞克斯大学获得细胞和分子生物学学士学位、英国诺丁汉大学获得癌症免疫治疗硕士学位、英国伦敦帝国理工大学获得生物化学博士学位。在加入默克之前，他曾在伦敦大学学院从事博士后研究，之后在英国生物技术公司 Spirogen（后被阿斯利康集团旗下全球生物制药分公司 MedImmune 收购）领导研究项目，归国后加入药明生物和睿智化学开展商务拓展及投资工作。

袁宁博士

Ning YUAN

联席首席商务发展官/Co-Chief Business Officer

复星医药/Fosun Pharmaceutical

袁宁博士现任上海复星医药集团副总裁兼联席首席商务发展官，负责复星医药的产品和技术引进及对外合作。袁宁博士在医药行业有着近20年的研发、营销、并购和BD工作经验，在复星医药工作期间帮助公司达成了多项具有影响力的产品合作。

As the Vice President & Co-Chief Business Officer, Dr. Ning Yuan leads licensing and partnering of pharmaceutical products and technologies in Shanghai Fosun Pharma. Dr. Yuan has been engaged in R&D, marketing, M&A and business development in the industry for nearly 20 years. During his working in Fosun Pharma, Dr. Yuan has made quite a few influential deals for the company.

Harm Jan Borgeld

亚太区合作负责人、副总裁/Head of Roche Pharma Partnering Asia

罗氏制药/Roche

Harm-Jan Borgeld, Head of Roche Pharma Partnering Asia is responsible for the negotiations of innovative, Asia sourced, deals to transform R&D strategic wants into global research and development plans to improve Roche’s external innovation portfolio with first in-class and best in-class compounds. Harm-Jan is based in Shanghai and is a member of the Leadership Team of Roche Pharma Partnering.

Having grown up in the Netherlands, had various careers and roles in the army, academia and pharmaceutical industry. He graduated in 1993 from Wageningen University, his passion was biochemistry and business administration.

He received 6 honors and awards, including 1st prize winner in McKinsey 2001 Business Plan Competition, Netherlands, and an award for Excellent Leadership as Lieutenant in the Dutch Army.

He conducted his PhD research at the Faculty of Medicine, Nagoya University in Nagoya, Japan in 1995 before finishing his Postdoctoral fellowship of Research Institute from Institute of Applied BioTechnology. His focus area was mitochondrial gene therapy, where he developed a novel approach to selectively remove mutated DNA from the mitochondria and creating a possible pathway for treatment options for patients. In 2001 he moved to the Netherlands for his MBA at Rotterdam School of Management, in 2002 to the US to study for his MBA at the Haas Business School. He graduated in 2003.

In 2003, he joined Kyorin Pharmaceuticals, in Germany, as Head BD where he negotiated 3 deals and created 2 business plans for the region Europe.

He spent most of his career at Merck Healthcare KGaA, over 15 years in various positions, he started in 2005 as Senior Licensing Manager in Business Development. In 2008 he became Global Project Team Leader, where he led the clinical development of an immune-oncology antibody. From 2010 he was the Vice President, Head Global Alliance Management. His group oversaw 110-120 global alliances in Research, Development, Commercial and 15-20 regional alliances in Latin America.

华烨博士

Ye HUA

董事长兼首席执行官/

Chairman and CEO

烨辉医药/BioNova Pharmaceuticals

华烨博士是烨辉医药科技有限公司（BioNova Pharmaceuticals）的创始人和CEO。基于填补未满足临床医学需求为出发点，建立国际领先的医药研发企业为目标，华博士和创业团队于2018年10月创立了烨辉，借力于实力卓著的资本支持，烨辉医药布局创新靶点的新药自主研发、同时也将海外优质在研阶段的创新小分子靶向及ADC药物引进中国进行临床开发及新药注册。凭借精干的研发团队、尖端的生物科技和充足的研发资金，烨辉医药致力于为中国和全球的患者提供临床急需的创新药物。

华博士拥有20多年的新药临床开发和全球新药注册的经验。在创立烨辉医药前，华博士曾担任和记黄埔医药资深副总裁，负责临床与注册部门。

Ye Hua, MD, MPH is the founder and CEO of BioNova Pharmaceuticals, a start-up biopharmaceutical company that is dedicated to the development and commercialization of innovative medicines for the treatment of cancers and other diseases with high unmet medical needs. The company focuses on building a robust pipeline through internal R&D programs, collaborations with global partners, and selective license and acquisitions. With a highly capable management team, cutting edge biotechnology, and substantial funding, BioNova is committed to delivering high quality innovative medicines to the patients in China and globally.

Dr. Hua is a senior drug developer who has 20+ years’ global clinical development and new drug registration experience with track records in the pharmaceutical industry. Prior to building up BioNova, Dr. Hua was Senior VP, Head of Clinical Development and Regulatory Affairs at Hutchmed, a leading R&D biotech company headquartered in Shanghai China.

朱凌宇博士

Lingyu ZHU

首席业务拓展官/Chief Business Development Officer

赛生医药/Sciclone Pharmaceuticals

朱凌宇博士在国际制药行业已经工作了20年的时间，他先后在跨国制药企业（美国辉瑞公司和强生公司）和本土创新制药企业（贝达药业）主持战略合作及对外投资业务。到目前为止，朱博士完成了28项总价值超过30亿美元的战略合作及对外投资项目，这其中就包括了2014 年 10 月贝达药业对美国 Xcovery公司2千万美金的战略投资并收购了恩沙替尼的中国权益，以及 2013 年5月贝达药业与美国安进公司在中国建立合资企业推动安进公司的帕妥木单抗在中国的注册报批和市场化。

Dr. Zhu has more than 20 years of experience in the pharmaceutical industry and worked with both global pharmaceutical companies (Pfizer and JNJ) and Chinese pharmaceutical company. He has done 28 strategic transactions (total value > US$3 billion) including the 2 recent landmark deals in China, the Joint Venture agreement between Amgen and Betta Pharma to commercialize Amgen’s Vectibix® (panitumumab) in China for colorectal cancer patients in May 2013, and the US$20 million strategic investment in Xcovery by Betta Pharma and acquired the China right of Ensartinib in October 2014.

李安康博士

Ankang LI

首席战略及财务官/Chief Strategy and Financial Officer

腾盛博药/Brii Biosciences

李博士是香港上市公司腾盛博药（HK2137）的首席战略及财务官，在投资银行、商务拓展与授权、法律以及生物医药研究领域有超过十年的卓越经验。加入腾盛博药前，李博士曾在拓臻生物担任首席财务官。李博士还曾任高盛医疗投资银行部执行董事和跨国制药公司默沙东亚太创新中心总监。李博士还曾先后在全球知名律所达维律师事务所和瑞格律师事务所工作，为客户提供资本市场和并购交易方面的法律咨询。在职业生涯更早阶段，李博士还曾在索克生物科学研究所从事博士后研究。

李安康博士从芝加哥大学获得法学博士学位，贝勒医学院获得生物医药博士学位，新加坡国立大学获得生物科学硕士学位，在复旦大学获得生物化学学士学位。他还是特许金融分析师持证人。

Dr. Li is Chief Financial Officer at Brii Biosciences. He has more than 10 years of experience in investment banking, business development, legal transaction and biomedical research. Before joining Brii Bio, he was the CFO of Terns Biopharmaceuticals to develop and deploy financial and corporate strategies and budget. Prior to Terns, Dr. Li was the Executive Director of Healthcare Investment Banking at Goldman Sachs responsible for Asia ex-Japan investment banking and led many high-profile IPOs for biotechnology and other healthcare clients. Dr. Li also worked in MSD Asia Pacific Innovation Hub, overseeing business development and licensing transactions in the region. Before that Dr. Li worked at international law firms, Davis Polk and Ropes & Gray, advising clients on M&A and investment transactions. Earlier in his career, he conducted postdoctoral biomedical research as Salk Institute in Dr. Ronald Evans’s lab.

Ankang Li received a Juris Doctor degree from the University of Chicago Law School, a Ph.D. degree in Biomedical Sciences from Baylor College of Medicine, a Master of Science degree in Biological Sciences from the National University of Singapore, and a Bachelor of Science degree in Biochemistry from Fudan University. He is also a chartered Financial Analyst (CFA).

尹正博士

Zheng YIN

管理合伙人/Partner

三一创投/Trinity Innovation (Beijing) Investment Management

三一创新（北京）投资管理公司是一家专注在生物医药创新领域的投资机构。创办三一创新（北京）投资管理公司之前，尹正博士曾任国投创新投资管理公司董事总经理，专注生物医药行业股权投资，主要投资项目有迪哲、亚盛、康希诺、瑞博、信达、博瑞等。尹正博士在生物医药领域积累了多层次、丰富的行业经验，在国外工作期间先后服务于生物技术公司与大型跨国制药企业Novartis，负责新药创制与项目管理；回国后在国内著名高等学府从事与生物医药相关的教学、科研、管理和咨询等工作，曾任南开大学药学院院长、药物化学生物学国家重点实验室副主任、清华大学基础分子科学中心执行主任等职务；受聘为多个国家级行业与科技专业委员会的成员。尹正博士还曾担任普华永道投资与并购咨询业务总监，开展生物医药行业投资与并购咨询业务。

尹正博士拥有南开大学学士学位和硕士学位，新加坡国立大学理学博士学位。

Trinity Innovation (Beijing) Investment Management Co., Ltd is an investment institution focusing on the field of biomedical innovation. Before starting the company, Dr. Yin Served as the managing director of SDIC Innovation Investment Management Co., Ltd., responsible for equity investment in the pharmaceutical and healthcare sector, such as Dizal, Ribo, Ascentage, CanSino, Bright-gene, Ribo and EpimAb. Dr. Yin Worked in both biotech and global multinational pharmaceutical companies Novartis, responsible for innovative drug discovery and project management; Previous positions include Dean of the School of Pharmacy of Nankai University, Deputy Director of the State Key Laboratory of Medicinal Chemical Biology, and Executive Director of the Center for Basic Molecular Science of Tsinghua University. He has been employed as a member of several national industry and science and technology professional committees. Dr. Yin Zheng also served as the PWC Investment and M&A of Consulting Director, and carried out investment and M &A consulting business in the Biomedical Industry.

Bachelor and Master degree from Nankai University; Ph.D. of Science, National University of Singapore.

沈丽丽女士

Lily SHEN

董事总经理/Managing Director

晨兴创投/MorningSide

沈女士于2010年加入晨兴创投，主要负责生物医药的投资管理，目前担任十余家生物医药/医疗服务创业公司的董事。沈女士具有18年生物医药/医疗健康领域的工作经验，深刻理解医疗健康尤其生物医药企业的机会和挑战。加入晨兴创投之前，沈女士在两家生物医药企业担任新药注册和商务拓展负责人。沈女士是复旦大学工商管理硕士，西安交通大学生物化学与分子生物学硕士。

Lily joined Morningside in 2010 and serves as board directors in more than ten Morningside portfolio companies. She has worked in life science industry for 18 years with rich experience in investment management and new drug R&D management in China. Lily received her master degree in M.B.A from Fudan University and Biochemistry and Molecular Biology from Xi’an Jiaotong University.

袁斌博士

Bin YUAN

联合创始人, 董事长兼首席执行官/

Co-Founder, Chairman, CEO

昂阔医药/OnCusp Therapeutics

袁斌博士是美国哥伦比亚大学分子生物学博士，康奈尔大学商学院MBA和南京大学生物化学学士。他是创业者和医药业务拓展，市场营销和新产品研发战略的资深专家，曾经在不同阶段为包括可瑞达（Keytruda），格列卫(Glivec) 在内的13个国际癌症药的成功做出过突出贡献。在创立OnCusp 之前，他担任基石药业首席战略官和首席商务官，作为最早高管之一，参与领导了从公司起步，上市到商业化转型的全过程，建立和管理过包括业务拓展、公共关系、研发项目管理及商业化团队等十余个职能部门，完成了与辉瑞，拜耳，Blueprint，Agios, EQRx 等近十项国际合作。在2016年11 月之前，他在美国工作学习了22年，曾任美国默沙东癌症类药业务拓展全球主管和执行总监，诺华癌症事业部产品生命周期管理全球主管和商务执行总监，卫材全球市场部癌症新产品战略高级经理，赛默飞世尔产品经理等职务，成功领导或参与了四十余个并购、转让及临床研发合作的业务拓展项目，作为项目组核心成员制订过5个癌症药的早期研发战略，负责过重磅癌症药Glivec和Afinitor在专利过期前的策略制定，并参加了肺癌药Zykadia的全球上市。

Dr. Bing Yuan is an entrepreneur and a seasoned business executive in business development and licensing (BD&L), marketing and new product strategy. He has made significant contributions to 13 approved global oncology drugs at various stages of product life cycle, including blockbusters such as Keytruda and Glivec. Before founding OnCusp, he was Chief Strategy and Business Officer at CStone Pharmaceuticals. As a senior executive from the beginning, he helped to build the company from startup to successful IPO and then becoming a commercial stage biopharma. At CStone, he established and managed over 10 departments, such as BD&L, public relations, R&D project management and commercial organization. He successfully reached close to 10 strategic partnerships with Pfizer, Bayer, Blueprint, Agios, EQRx, etc. Before joining CStone in November 2016, he spent 22 years in the USA. He was Executive Director and Global Lead of Oncology BD&L at Merck (MSD), Global Head of Life Cycle Strategy and Executive Director at Novartis Oncology, Global Oncology Marketing Lead at Eisai, and Product Manager at Thermo-Fisher. He successfully led or contributed to over 40 M&A, licensing and Keytruda clinical collaboration deals. As a core member of the global project team (GPT), he played a key role in designing development strategy for 5 oncology drugs. He used to lead Glivec and Afinitor brand life cycle strategy and participated in global launch of Zykadia in ALK+ lung cancer. Dr. Yuan holds a Ph.D. in Molecular Biology from Columbia University, an MBA from Cornell University and B.S. of Biochemistry from Nanjing University.

范国煌博士

Guohuang FAN

董事长/CEO

艾美斐生物/Immunophage Biotech

范国煌博士是医学专家，药理学专家，国家自然科学奖获得者，中国科学院“百人计划”学者，同济大学兼职教授，博士生导师。范国煌博士曾担任世界制药巨头葛兰素史克研发中心管理新药研发团队负责人，开展针对重大疾病的药物研发，完成多种新药的临床前研究，所领导的多项新药开发项目进入临床试验。范国煌博士拥有25年恶性肿瘤和神经退行性病变等重大疾病的药理学研究经验，在国际重要期刊上发表50余篇研究论文，获得10余项发明专利。曾先后被评为国家自然科学奖（二等奖）、中华医学科技奖（一等奖）、上海市科技进步奖（一等奖）、美国NIH特别神经科学奖、2021年南京科技顶尖专家等荣誉。

Blake Salisbury

Senior Vice President, Business Development

信达生物/Innovent Biologics

Mr. Blake Salisbury is responsible for BD activities at Innovent, where he has led the partnering efforts for cross-border deals with Sanofi, Lilly, Roche, Coherus, Alector, Hanmi, MD Anderson, and others. He received his MBA from Thunderbird Graduate School of Global Management. He has 30 years of experience in pharma/biotech, primarily in business development (23 years), but also in sales, marketing, and pricing. Prior to joining Innovent, Blake spent almost 24 years with Eli Lilly and Company where he closed over 50 transactions of various types.

张继国先生

Jeffrey ZHANG

首席商务官兼首席运营官/CBO and COO

斯微生物/StemiRNA Therapeutics

张继国先生现任斯微生物首席商务官，在加入斯微生物之前，张继国先生先后在药明生物担任疫苗业务副总裁，药明康德担任战略副总裁。张继国先生还曾在GSK疫苗总部担任新兴市场副总裁兼中国管理委员会成员。他的职业生涯从销售开始，曾在辉瑞中国和西安杨森任职，先后担任产品经理，新业务发展负责人，战略市场总监，在战略、业务发展、营销管理等方面积累了丰富经验。张继国先生也是虹博基因的创始人，曾以优异的成绩毕业于北京大学医学部以及北京大学国家发展研究院。

Jeffrey Zhang is the Chief Commercial Officer of Microbiology. Prior to joining SMC, Jeffrey Zhang served as Vice President of Vaccine Business at WuXi Biologics and Vice President of Strategy at WuXi AppTec. Jeffrey Zhang also served as Vice President of Emerging Markets and member of the China Management Committee at GSK Vaccine Headquarters. He started his career in sales, working for Pfizer China and Xi'an Janssen, where he served as Product Manager, Head of New Business Development, and Director of Strategic Marketing, gaining extensive experience in strategy, business development, and marketing management. Jeffrey Zhang is also the founder of Hongbo Genetics and graduated with honors from Peking University School of Medicine and Peking University National Development Institute.

Translated with www.DeepL.com/Translator (free version)

江雪博士

Xue JIANG

管理咨询业务大中华区负责人/Consulting Services Leader

科睿唯安/Clarivate Analytics

江雪博士现任科睿唯安（Clarivate）大中华区管理咨询业务（含生命科学与医疗健康）负责人。

他有超过13年生命科学与医疗健康领域行业经验，包括10年多的管理咨询和行业分析经验，以及2年工业研发和技术转移上的经验。

加入科睿唯安之前，江雪博士曾就职于药明康德上海总部，负责建立差异化的行业分析和咨询能力。他也曾就职于欧睿国际北美分部，为《财富》500强企业、领先新创公司、政府部门和投资机构等客户提供管理咨询和行业研究服务，并接受过美联社、Financial Post和CTV News等媒体采访，阐释行业观点。

他拥有美国Rutgers罗格斯大学（与UMDNJ新泽西医科和牙科大学联合项目）生物医学工程博士学位、上海交通大学学士学位（Top5%）以及多项发明专利。他还致力于消除贫困、科技普及和战胜疾病等方面的公益和慈善事业。

Dr. Xue Jiang is the Consulting Service Leader (including Life Sciences and Healthcare) of Greater China at Clarivate Consulting.

He has 13+ years of industry experience in the life sciences and healthcare sector, including more than 10 years of experience in management consulting and industry analysis, and 2 years in industrial R&D and technology transfer.

Prior to joining Clarivate, Dr. Jiang worked at WuXi AppTec headquarters in Shanghai, where he was responsible for building differentiated industry analysis and consulting capabilities. He has also worked for Euromonitor International in North America, where he has provided management consulting and industry research services to Fortune 500 companies, leading startups, government agencies and investment firms, and has been interviewed by media outlets such as the Associated Press, Financial Post and CTV News to share industry insight and perspectives.

He holds a Ph.D. in biomedical engineering from Rutgers University (a joint program with UMDNJ, University of Medical & Dental of New Jersey), a bachelor's degree from Shanghai Jiao Tong University (Top5%), and several utility patents. He is also committed to public welfare and philanthropic causes such as poverty eradication, promotion of science & technology, and the fight against disease.

罗天健先生

Kenneth Law

财务咨询合伙人/Financial Advisory Partner

德勤/Deloitte

罗天健先生是德勤中国并购交易咨询合伙人以及德勤中国生命科学与医疗行业财务咨询核心成员。他在审计、海外资本市场、尽职调查及财务咨询服务等领域有15年的专业经验，专长于兼并收购交易相关的财务尽职调查、收购价值建议、并购谈判支持等领域，并已为超过150宗国内并购案和60宗跨境并购案提供建议。罗先生曾在英国伦敦审计、资本市场和并购交易团队工作8年，在欧洲完成近50件企业上市和并购交易案。

胡奇聪博士

Qicong HU

董事总经理，全球合伙人/Managing Director and Partner

波士顿咨询/Boston Consulting Group

胡奇聪博士是波士顿咨询公司（BCG）的董事总经理，全球合伙人，BCG医疗保健专项的核心领导。

胡博士他在生物医药、生命科学等多个领域拥有近15年的学术研究、丰富的行业和项目经验。相关项目经验包括：帮助多家知名国内外医药和生命科学企业制定中长期发展战略；帮助多家企业识别各疾病治疗领域的国内外项目机会；帮助多家生物药企业规划中长期战略；实现研发组织管控体系设计和转型；支持多家企业上市新产品，包括第一个肿瘤免疫产品上市工作等。

胡博士是斯坦福大学生物医学博士，曾在《科学》杂志上发表过一作文章，被Faculty of 1000选为当年排名第二生物医学文章。

Dr. Qicong Hu is a Managing Director and Partner of Boston Consulting Group (BCG), and a core leader of BCG Greater China Health Care practice area.

Dr. Hu has 15- year experience in health care. He served leading clients on high impact programs, with deep expertise in the space of biopharma (R&D, product launch, biologics/biosimilars, marketing access, life science, BD/CD and emerging therapies.

His major project experience includes: Led strategy, portfolio planning/upgrading and early-stage pipeline screening through AI and machine learning for a leading local client; redesign of R&D organizations to improve productivity, including org re-structure, decision-making processes, operational efficiency uplift, and KPIs & incentive redesign; Strategy design and execution with deep understanding reimbursement pathway and Payer dynamics; Served top life science players on China strategies including market landscaping, GTM and digital strategies; Served local and MNC client to scout for innovation/targets and support in deal sourcing, cDD and deal transactions, etc.

Dr. Hu earned a Ph.D. in Biomedical Sciences from Stanford. He published 8 articles in world renowned journals, including a first-author paper published on the journal Science.

周高波先生

Gaobo ZHOU

首席投资官/Chief Investment Officer

先声药业/Simcere Pharmaceutical

周高波，先声药业首席投资官，负责公司创新药投资和合作业务的拓展、新投资平台建设以及战略规划与实践。

加入先声药业之前，周高波先生在麦肯锡公司担任全球董事合伙人和大中华区医疗咨询联席负责人，拥有十五年医疗行业管理咨询经验，致力于为领先的制药、生物科技、医疗器械、生命科学投资公司提供战略和管理咨询服务，深入探索中国医改和创新环境下的企业战略、创新商业模式、数字化转型、投资合作，并组建了行业内最大的医疗领域管理咨询团队。此前，他在人类基因组科学公司(HGSI)从事抗体和融合蛋白药物的研发工作。

周高波先生拥有杜克大学商学院的工商管理硕士学位，马里兰大学生物化学硕士学位和复旦大学的遗传学本科学位。

Mr. Zhou Gaobo is the Chief Investment Officer of Simcere Pharmaceutical Group (2096.HK). He is in charge of the company's innovative drug investment and business development, establishment of new investment platforms, and investment strategy planning and practice.

Prior to joining Simcere, Mr. Gaobo Zhou was a Partner at McKinsey & Company and co-leader of the Greater China Healthcare practice. He has fifteen years of experience in management consulting in the healthcare industry. He worked with leading pharmaceutical, biotechnology, medical device, and life science investment companies on a broad range of topics in the context of China's Healthcare Reform and innovation, including strategy, business model innovation, digital transformation, and investment and partnership. He also built the largest healthcare management consulting team in the industry. Previously, he also worked at Human Genome Sciences (HGSI) in antibody and fusion protein drug development.

Mr. Gaobo Zhou holds an MBA from Duke University, a Master's Degree in Biochemistry from the University of Maryland, and a Bachelor's Degree in Genetics from Fudan University.

姜华博士

Hua JIANG

商务拓展负责人/Head of Business Development

和誉生物/Abbisko Therapeutics

姜华博士，和誉医药商务拓展负责人。姜博士具有十余年的药物研发、商务合作及团队管理经验，对于创新药项目的各个阶段都有较深刻的认识。在加入和誉之前，姜博士曾先后于勃林格殷格翰（BI）和雅培药品业务（Abbott）的外部创新部门担任管理岗位，负责创新与对外合作业务。加入BI之前，姜博士还曾在诺华生物医学研究中心工作近十年，担任研发项目负责人，带领团队从事创新药物的早期研发工作。姜华博士目前领导和誉医药的商务拓展团队，负责全球商务运作和业务拓展，包括产品和技术的引进、合作开发等。

Hua worked in pharmaceutical industry for more than 13 years after his Ph.D. in Biology training from CAS and academic research work in SJTU. Before joining Abbisko, Hua worked for Abbott pharmaceutical division as Director of External Innovation, responsible for asset scouting and licensing. Before that Hua worked in Beohringer Ingelheim as AD of Global External Innovation based in Shanghai. More than external innovation, Hua worked almost 10 years (2009-2019) in China Novartis Institute for BioMedical Research (NIBR) as scientist and then project leader, gained hands-on experience for early stage drug discovery.

朱向阳博士

Xiangyang ZHU

总经理/CEO

华奥泰生物/Huaota Biopharm

朱向阳博士，“国家引才计划专家”，“浙江省领军人才”，是生物制药研发和工艺开发方面的专家，在单抗筛选和鉴定，双靶点抗体的工程改造，细胞株的建立，工艺开发, 技术转移, 中试厂房的设计和建设等领域拥有丰富经验。朱向阳博士目前是上海华奥泰生物股份有限公司总经理，负责公司的全球生物制药研发。领导华奥泰生物共计获得17个新药临床批件，推进11个项目至不同临床开发阶段，完成40个新药专利全球申请，领导并建立了一支400多人的创新团队、完成了1000L中试生产平台，GMP质量体系、15000平米的大分子制药商业化生产平台的搭建和完善。

朱向阳博士曾长期在勃林格殷格翰（BI）的不同领域和地点工作（美国，德国，中国），领导和参与了20多个单抗或双靶点抗体项目的研究，是Risankizumab早期项目负责人和发明人，该产品目前已由Abbvie上市。朱向阳博士在伊利诺伊大学获得免疫学博士学位。

Dr. Zhu is an expert in antibody drug discovery and process development with more than 18 years of industrial experience. He has extensive experience in antibody drug discovery, process development, and manufacture facility construction. Dr. Zhu is the CEO for both Huaota Biopharm and Huabo Biopharm (members of Huahai Pharm), leads its global biotherapeutic research. Prior to join Huahai, he worked at Boehringer Ingelheim for more than 8 years in different function areas at multiple locations ( Ridgefield, USA; Biberach, Germany; and Shanghai, China). He led and engaged in over 20 global BI biological research projects including current clinic Phase I-III projects and market products; Dr. Zhu obtained his PhD in microbiology and immunology from the University of Illinois at Chicago .

俞文冰先生

Wenbing YU

总经理助理/Assistant General Manager

君实生物/Junshi Biosciences

俞文冰先生现为君实生物总经理助理，分管投融资，是公司香港上市、科创板上市和再融资等项目组主要成员之一，目前主要负责公司投资人沟通，公司的股权融资，以及对外投资等业务。在加入君实生物之前，俞先生拥有超过12年金融行业工作经验，曾经工作于中海基金，长江证券，广发证券和光大证券，曾多次获得新财富、水晶球等分析师评选的第一第二名，曾多次获得深交所、中国证券业协会等评选的优秀研究课题。

Mr. Yu is the assistant general manager of Junshi Biosciences, in charge of investment and financing. He is a core member of company’s financing projects like HKEX listing, SSE STAR Market listing and refinancing. Currently, he is mainly responsible for the company's investor communication, equity financing, and external Investment related businesses. Before joining Junshi, Mr. Yu has more than 12 years of experience in the financial industry. He previously held positions in Zhonghai Fund, Changjiang Securities, GF Securities and Everbright Securities. He also won Crystal Ball Sell-Side Analysts Awards and the Best Analyst of New Fortune for many times, with many excellent research projects selected by the SZSE and the SAC.

韩净先生

Jing HAN

首席商务官/CBO

康宁杰瑞/Alphamab Oncology

韩净先生目前供职于康宁杰瑞担任首席商务官职位，主要负责公司商业化运营，上市前临床协调部工作以及外包产品（石药先声）商业化合作。在此之前，韩净先生担任嘉和生物高级副总裁职位，负责组建营销团队及上市前各项商业化工作。在担任上海君实生物副总经理期间，建立营销部搭建团队至550人，制定以大医学概念为前提的市场销售策略，2018年在比竞争对手少一半人员的情况下完成7.74亿销售（10个月），费用比仅48%（信达76%，百济2020年上市第一年90%以上）；开展肺肝食管淋巴瘤等癌肿ISS项目80余项，部分如肝内胆管癌（PD-1+仑伐+Gemox，40%，上海中山医院樊嘉周俭）ORR达90%，后正式立项三期三臂临床，二期数据列入2021年CSCO胆管癌治疗指南。作为临床医生出生的韩净先生也曾在罗氏制药、拜耳医药、阿斯利康、勃林格殷格翰、默沙东等大型跨国药企均有过从业经验。

钱晶博士

Dianna QIAN

合伙人/Partner

鼎豐生科资本/Pivotal bioVenture Partners China

钱晶女士于2018年成为鼎豐生科資本合伙人。在此之前，她任职于两家知名的美元基金（富达亚洲风险投资与方源资本），主导了不同阶段的医疗行业投资，是医疗团队的核心成员之一。在此之前，钱晶女士是勃林格殷格翰（BI）中国区的副总裁，负责企业战略与业务发展，以及新产品规划两个部门。在此期间，钱晶女士领导了BI与Eli Lily的战略联盟，并主导了多个不同治疗领域的产品授权。钱晶女士的职业生涯开始于波士顿咨询（BCG），之后成为了麦肯锡中国与美国办公室的项目经理，专注于医疗健康领域。

钱晶女士于2004年取得美国宾夕法尼亚大学沃顿商学院MBA。

Dianna joined Pivotal China in 2018 as a Partner. Dianna has 20+ years of healthcare expertise; previously as core healthcare investment member at Fidelity Asia Growth Partners and FountainVest Partners. Prior to that, Dianna worked as Vice President at Boehringer Ingelheim China in charge of Business Development and New Product Planning, and Engagement Manager at McKinsey’s China and US offices specializing in healthcare sector.

Dianna graduated from Wharton Business School with an MBA degree in 2004.

王浩洵博士

Haoxun WANG

早期创新合作经理/Manager,Early Innovation Partnering

强生创新/Johnson & Johnson Innovation

作为强生亚太创新的早期创新合作经理，王浩洵的主要职责是在亚太地区制定合作策略、积极寻找高潜力的早期合作研发项目并与新兴的抗感染领域和技术平台公司、企业家、风险投资机构和学术研究机构建立策略合作，以加速区域内创新。浩洵在美国新泽西罗格斯大学获得药学博士学位。

Haoxun Wang is the Early Innovation Partnering Manager at Johnson & Johnson Innovation, Asia Pacific. In this role, Haoxun is responsible for identifying strategic collaboration opportunities and building scientific connectivities with the emerging Infectious Diseases & Vaccines and Platform companies, entrepreneurs, venture capital groups, academic and research institutes across Asia Pacific. Haoxun holds a Ph.D. in Pharmaceutical Sciences from Rutgers University.

郭俊慧女士

Amanda GUO

BD副经理/BD Associate Manager

信达生物/Innovent Biologics

2017年2日加入信达，目前主要负责国内BD，主导完成了葆元、劲方、来凯，参与和支持了赛诺菲、礼来、罗氏、亚盛、Coherus、MD Anderson、Etana合作交易。

Joined Innovent in Feb, 2017, and is currently responsible for China BD, and has led recent Innovent transactions with AnHeart, GenFleet, and Laekna, and has also supported the SVP of Business Development for in establishing several of Innovent’s existing partnerships with Sanofi, Lilly, Roche, Ascentage, Coherus, MD Anderson, Etana etc.

孙军先生

Jun SUN

商务拓展副总裁/Vice President, Business Development

泽璟制药/Zelgen Biopharmaceuticals

姜非博士

Fei JIANG

首席投资官（大中华区）/CIO (Greater China)

康哲药业/CMS

华东理工大学化学工程学士；美国雪城大学化学工程博士。现担任康哲药业首席投资官（大中华区），负责集团战略投资和合作业务的拓展、新投资平台建设以及战略规划与实践。

曾任职于美国Cell Genesys、AlphaVax及沈阳三生制药等多家国内外生物医药企业，从事工艺开发、研发管理和业务拓展工作；后任职于中诺创投、健壹资本和洪泰基金等专业医疗投资机构，专注于创新药物与医疗器械的风险投资。

Dr. Fei Jiang is the Chief Investment Officer (Greater China) of CMS Group (0867.HK). He’s in charge of CMS’ strategic investment as well as business development in Greater China Region.

Dr. Jiang got his Ph.D. degree in chemical engineering from Syracuse University, New York at 2006, after receiving his bachelor degree, also in chemical engineering, from East China University of Science and Technology, Shanghai at 1998.

After graduation, he joined Cell Genesys at South San Francisco, California, to develop cancer cell-based immunotherapy products, and AlphaVax Inc. at Research Triangle Park, North Carolina, to develop RSV and CMV vaccines.

Dr. Jiang returned to China and joined in 3SBio (1530.HK) at 2010. He served as R&D Manager, and later R&D Director till 2013. He shifted his role to BD Director since 2013, and took care of business development and strategic alliance management for 3SBio. He joined in healthcare investment business since 2017, and served as the Executive Director of Guijing Capital and Sinopharm Capital, and the Managing Director of Aplus Capital successively.

江雪博士

Xue JIANG

管理咨询业务大中华区负责人/Consulting Services Leader

科睿唯安/Clarivate Analytics

江雪博士现任科睿唯安（Clarivate）大中华区管理咨询业务（含生命科学与医疗健康）负责人。

他有超过13年生命科学与医疗健康领域行业经验，包括10年多的管理咨询和行业分析经验，以及2年工业研发和技术转移上的经验。

Dr. Xue Jiang is the Consulting Service Leader (including Life Sciences and Healthcare) of Greater China at Clarivate Consulting.

吴琼先生

Alex WU

高级副总裁及首席商务官/SVP and CCO

药明巨诺/JW Therapeutics

吴琼，现任药明巨诺首席商务官、高级副总裁，推动公司首个CAR-T产品倍诺达®从上市到商业化的迅速转型。扎根医疗行业28年，具有丰富的多产品线商业运营、战略规划及管理经验。吴琼曾是默沙东副总裁兼专科业务董事总经理，领导了多个产品领跑全球市场。他还曾先后在百特、西安杨森等跨国医疗公司担任要职，进行业务模式创新, 取得了卓越的商业化成果。吴琼拥有中欧国际工商学院高级管理人员工商管理硕士（EMBA）学位。

Alex Wu, Chief Commercial Officer (CCO) and Senior Vice President (SVP) of JW Therapeutics, has accelerated first product commercialization. Alex has 28 years’ experience in portfolio commercial operation, strategy planning and management in healthcare industry. Before joining JW Therapeutics, Alex was Vice President and Managing Director of Hospital Specialty Business in MSD China, during which he has led plenty of products overriding global market. Prior to that, he also served with key position in Baxter, J&J and other MNCs. He created innovative commercial model and achieved outstanding outcome. Alex has obtained his EMBA (Executive Master of Business Administration) degree from China Europe International Business School (CEIBS).

王清梅博士

May Wang

资深副总裁/Senior Vice President

和黄医药/HUTCHMED

王清梅博士负责领导和黄医药的商务开发及战略合作。她深度参与和黄医药和所有合作伙伴（包括阿斯利康，雀巢健康科学及礼来公司）的互动与协商，在积极联络和推动执行方面发挥了关键作用。

王博士于2010年加入和记黄埔医药。此前，她任职美国礼来制药公司，负责礼来在中国及亚洲的生物研发。在礼来工作的16年间，领导过数个在传染病、炎症及抗肿瘤等领域的研发团队，共同发明了多个候选药物，包括2011年上市的丙肝创新药INCIVEK™（telaprevir, LY570310）。王博士著有50余篇文章，拥有多项国际专利，并担任过数个专刊和国际基金会的评委。王博士获得美国普渡大学的生物学博士学位。

Dr. Wang heads all alliance management and business development for the company. She has been instrumental in engaging with, negotiating, executing and very actively liaising with all our development partners, including AstraZeneca, Nestlé Health Science, and Eli Lilly.

Prior to joining HMP in 2010, Dr. Wang spent 16 years with Eli Lilly and was the Head for Asian Biology Research, responsible for establishing and managing research collaborations in China and Pan-Asia. Dr. Wang has broad drug discovery and development experience spanning several therapeutic areas including infectious diseases, inflammation and oncology. She was a co-inventor for several drug candidates including the blockbuster drug INCIVEK (telaprevir, LY570310) launched in 2011 for treatment of HCV infection.

Dr. Wang has numerous patents, published more than 50 peer-reviewed articles and has given dozens of seminars and plenary lectures. She received her Ph.D. in Biology from Purdue University, USA.

臧鹏博士

Peng Zang

中国区业务拓展负责人/Head of Business Development, China

科济药业/CARsgen Therapeutics

臧鹏博士，科济药业中国区业务拓展负责人兼首席执行助理。负责中国区研发及商业化业务合作的拓展及支持科济药业全球业务拓展工作；负责科济药业产品管线的规划及管理。臧鹏拥有10余年的医药行业医学、市场、产品管线战略规划经验。加入科济药业之前，臧鹏担任上海罗氏制药有限公司的血液及早期新产品领域战略规划负责人，并在葛兰素史克、百时美施贵宝等公司有多年研发、医学及市场管理经验。

Dr Peng Zang, Head of Business Development, China and the Chief Executive Assistant to Chairman. Dr Zang is leads the business development activities of CARsgen in China, support the global BD activities, and leads the portfolio planning and management in CARsgen. Dr Zang has more than 10 years professional experiences of medical, marketing, and portfolio strategic planning in pharmaceutical industry. Prior to joining in CARsgen, he served as Strategic Planning Lead for Hematology and Early Assets in Roche China. Dr Zang has also taken multiple R&D and commercial roles in big multi-national pharmaceutical companies, including GSK and BMS.

部分已确认路演企业

Confirmed roadshow companies

南京艾美斐生物医药科技有限公司是一家临床阶段的生物制药公司，是由美籍华裔科学家范国煌博士和加籍华裔科学家王建飞博士主导的新药研发公司。

公司注重研究疾病的致病机理，深入发掘新靶点，围绕恶性肿瘤、自身免疫性疾病、神经退行性疾病等重大疾病开展新药开发，已拥有超过20条新药研发管线，其中第一梯队的全球创新的项目已分别获得6个美国FDA临床研究和中国CDE临床研究批件（IND），并在中国、美国、澳大利亚等国开展全球多中心临床研究。第二梯队的6个全球创新的新药研发项目已经入CMC、安评等临床前开发阶段，预计2022年三季度进入临床试验。公司拥有先进的小分子和大分子药物筛选和测试平台，已成功完成针对包括GPCR类靶点在内的近二十个新靶点药物筛选，是公司可持续发展的重要基石。

艾美斐医药于2018和2021年分别成立上海研发中心、澳大利亚全资子公司和美国全资子公司，以实现全球化布局。公司于2020年被认定为国家高新技术企业，2021年入选南京市培育独角兽企业。

nanjing immunophage biomedical technology co., ltd. is a clinical-stage biopharmaceutical company led by Chinese American scientist Dr. Guohuang Fan and Canadian Chinese scientist Dr. Jianfei Wang.

The company focuses on researching disease causation mechanisms, exploring new targets, and developing new drugs around major diseases such as malignant tumors, autoimmune diseases, and neurodegenerative diseases, etc. It has over 20 new drug development pipelines, of which the first tier of global innovation has been awarded 6 U.S. FDA clinical studies and China CDE clinical study approvals (IND), respectively. Australia and other countries. The second tier of six globally innovative new drug development projects have entered the preclinical development stage such as CMC and safety assessment, and are expected to enter clinical trials in the third quarter of 2022. The Company has an advanced small and large molecule drug screening and testing platform and has successfully completed drug screening for nearly 20 new targets, including GPCR-like targets, which is an important cornerstone of the Company's sustainable development.

Amphipharma established its Shanghai R&D center, a wholly owned subsidiary in Australia and a wholly owned subsidiary in the U.S. in 2018 and 2021, respectively, to achieve globalization. The company was recognized as a national high-tech enterprise in 2020 and selected as a Nanjing cultivated unicorn enterprise in 2021.

Translated with www.DeepL.com/Translator (free version)

领诺医药是一家基于自主技术平台的创新药物研发商，公司以穿越血脑屏障的大分子递送技术和选择性补体抑制为核心，以针对严重罕见病的孤儿药开发为突破口，期望利用自主或合作开发模式快速进入海内外成熟药物市场。

领诺医药自主开发了独有的血液半衰期延长（长效）、穿越血脑屏障等专利技术，并基于相关平台技术开发针对严重罕见病的孤儿药，包括补体靶向的抗体、重组蛋白类药物。研发管线覆盖针对新靶点、新机制、新适应症的First-in-class（FIC）产品，以及平台技术赋能、针对成熟靶点的Best-in-class（BIC）产品。

Linno Pharma is an innovative drug developer based on its own technology platform. With the core technologies of macromolecule delivery across the blood-brain barrier and selective complement inhibition, LonoPharma takes the development of orphan drugs for serious rare diseases as a breakthrough point and expects to enter the mature drug markets at home and abroad rapidly by using independent or co-development mode.

Linno Pharma has developed proprietary technologies such as blood half-life extension (long-acting) and blood-brain barrier crossing, and based on these platforms, we are developing orphan drugs for serious rare diseases, including complement-targeted antibodies and recombinant protein drugs. The R&D pipeline covers First-in-class (FIC) products for new targets, new mechanisms and new indications, as well as Best-in-class (BIC) products for mature targets enabled by platform technologies.

上海华奥泰生物药业股份有限公司（以下简称 “华奥泰”）成立于2013年9月，为浙江华海药业股份有限公司的子公司。

自成立以来，华奥泰持续专注于创新与发展，已建成完善的一体化生物新药研发平台和体系，包括单抗、双抗、融合蛋白及ADC等药物研发平台和符合GMP标准的原液和制剂中试平台。华奥泰原液生产采用一次性技术，引进了GE公司全球领先的200L和1000L即抛式生物反应器；制剂车间配有整套德国BOSCH进口的西林瓶和预充针罐装线，可支持各类给药方式；检测平台配有各类高精度的先进分析和检测设备；同时也建立了完善的质量保证体系用于支持生产、注册和临床研究。

自主研发驱动内部创新，公司产品管线丰富，覆盖肿瘤、自身免疫疾病和眼科疾病等重大疾病领域，目前在研项目超过20个，其中多个已进入临床研究阶段，正在美国、新西兰和中国开展临床试验。2019年华奥泰被认定为“国家高新技术企业”，先后承担并完成了多项上海市和浙江省科技项目，已申请国内外发明专利多件。

在生物药品蓬勃发展的当下，本着“品质铸就品牌，进取创造未来”的宗旨，华奥泰人脚踏实地、积极创新，始终致力于为全球市场提供高质量、高水平的生物新药，满足广大患者对可及性高、可负担性强生物新药的需求，实践创新改变世界的愿景。

Shanghai Huaota Biopharmaceutical Co., Ltd. (aka ‘Huaota’) was established in September 2013. Huaota is a subsidiary of Zhejiang Huahai Pharmaceutical Co., Ltd.

Driven by innovation and development, Huaota has built comprehensive and integrated platforms to develop novel biologics. The R&D platform at Huaota supports the identification and development of new monoclonal antibodies, bispecific antibodies, fusion proteins, ADC drugs, etc. Empowered by an effective quality system，the pilot platform for DS and DP production is in compliance with applicable GMP standards and received the Manufacture License of Pharmaceutical Production in 2020. Disposable technology and the world's leading 200L and 1000L disposable bioreactors from GE were employed in the DS pilot production. The DP workshop is equipped with complete sets of vials and prefilled syringe filling lines imported from BOSCH Germany, capable of supporting the production of up to 17,000 PFS/hour and 12,000 vials/hour. The quality control lab has a variety of advanced analytical instruments fulfilling the analytical needs, such as product release and stability studies, of supporting production, registration, and clinical trials.

Independent research and development drive innovation. Huaota has a diverse product pipeline covering therapeutic areas such as tumors and autoimmune diseases. At present, there are over twenty projects under development. Many of them have obtained IND approval and multiple clinical trials are undertaken in the United States, New Zealand, and China. Over the years, Huaota has completed many science and technology projects in collaboration with universities, research institutes, and other research organizations in China and globally. In 2019, Huaota was certified as High- and New-Technology Enterprise. By now, Huaota has applied for several domestic and international invention patents.

In today’s fast lane of biopharmaceuticals development，Huaota is inspired by the mission of ‘Innovation brings the future, Quality makes the brand’. With a culture of open-mindedness, innovation, and dedication Huaota continues to develop a variety of innovative yet affordable biological drugs to meet the unmet medical needs globally.

科济生物是一家在中国及美国开展业务的生物制药公司，主要专注于治疗血液瘤和实体瘤的创新CAR-T 细胞疗法。

自2014年开始运营以来，我们已内部开发多项新技术以及拥有全球权益的产品管线，以解决CAR-T 细胞疗法面临的重大挑战，比如提高安全性、提高实体瘤的疗效，和降低治疗成本。我们的产品管线包括升级版的全人源靶向BCMA CAR-T，全球唯一获得IND临床试验许可的全球潜在同类首创Claudin18.2 CAR-T, 以及全球潜在同类首创的GPC3 CAR-T。对于CAR-T细胞疗法，我们已经在中国、美国、加拿大获得一共8个IND批件，是目前中国CAR-T公司中最多的。

在由经验丰富的学术专家和行业资深人士组成的管理团队的领导下，我们建立了一个整合的细胞治疗平台，内部能力涵盖靶点发现、先导抗体开发、临床研究和商业化规模生产。

Carsgen is biopharmaceutical company with operations in China and the U.S. focused on innovative CAR-T cell therapies for the treatment of hematological malignancies and solid tumors.

Since our inception in 2014, We have internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR-T cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors and reducing treatment costs. Our product pipeline include an upgraded fully-human BCMA CAR-T (CT053), globally potential first-in-class Claudin18.2 CAR-T (CT041) with the only IND clearance, and globally potential first-in-class GPC3 CAR-T (CT011). we had obtained eight IND clearances for CAR-T therapies in China, the United States and Canada, ranking the first among all CAR-T companies in China.

Led by an experienced management team of academic professionals and industry veterans, we have built an integrated cell therapy platform with in-house capabilities that span from target discovery, lead antibody development, clinical studies to commercial-scale manufacturing.

西比曼生物科技集团（Cellular Biomedicine Group）是一家以临床研究为基础的生物制药公司，致力于开发治疗癌症的免疫细胞治疗产品和治疗退行性疾病的干细胞治疗产品。

西比曼生物科技集团开发治疗癌症和退行性疾病的具有自主知识产权的细胞疗法。我们采用经过验证的GMP车间生产的产品在中国开展肿瘤免疫学及干细胞临床试验。我们在中国的GMP车间涵盖12条独立的细胞生产线，并全部依据中国和美国的GMP标准进行设计和管理。

A clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases.

Cellular Biomedicine Group, Inc, a wholly-owned subsidiary of CBMG Holdings, develops proprietary cell therapies for the treatment of cancer and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards.

关键议题

Key lssue

• 【圆桌讨论】差异化创新：全球疫情下的生物医药合作新趋势

• 【圆桌讨论】全球化vs本土化：大药企的外部创新战略变革

• 【圆桌讨论】进程加速：全球创新药企的商业化新征程

• 【圆桌讨论】License-Out大爆发：新药“出海”的关键考量

• 【圆桌讨论】唯快不破：全球同步临床的策略构建与商业化合作

• 【圆桌讨论】中国vs全球：源头创新与商业模式探索

• 【圆桌讨论】“引入+自研”：差异化产品管线的布局策略

• 【圆桌讨论】理性回归：资本寒冬下的医药投资新风向

• 【圆桌讨论】IPO 2.0时代：药企上市及上市后的发展路径

• “BD内循环”：中国Big Pharma+Biotech的合作创新

• 以临床价值为导向：药品的国际化能力构建

• 引进来与走出去：本土大药企的转型创新之路

• 全球合作创新：抗体药物开发与商业的全球化

• 资本市场洞察：药企并购重组与商业合作趋势

• 案例：天演药业的出海交易之路

• 案例：开放式创新：华东医药的全球合作探索

• 案例：战略合作：MNC的交易实践分享

• 模拟交易大师课：药企全球授权许可与合作交易

【Panel Discussion】Differentiated Innovation: New Cooperation Trend of Biomedical Industry under the Global Pandemic

【Panel Discussion】Globalization vs. Localization: Big Pharma's External Innovation Strategy Revolution

【Panel Discussion】Accelerating Process: A New Commercialization Journey of Global Innovative Drug Companies

【Panel Discussion】License-out Explosion: Key Considerations for New Drugs' Globalization

【Panel Discussion】Nothing but Fast: Strategy Construction and Commercial Cooperation of Global Synchronous Clinical Trials

【Panel Discussion】China vs. Global: Source Innovation and Business Model Exploration

【Panel Discussion】"Licensing-in and Self-develop" :the Differentiated Product Pipeline Layout Strategy

【Panel Discussion】Rationality Return: Pharmaceutical Investment New Trend in the Capital Winter

【Panel Discussion】IPO 2.0 Era: The IPO and Post-IPO Development of Pharmaceutical Companies

"Domestic BD": Collaborative Innovation of Chinese Big Pharma and Biotech Companies

Clinical Value-oriented: Construction of Pharmaceutical Internationalization Capability

Licensing-In and Licensing-Out: The Transformation and Innovation of Traditional Chinese Big Pharma

Global Collaborative Innovation:Antibody Drug Development and Global Commercialization

Capital Market Insight: M&A and business cooperation trends of pharmaceutical companies

Case:Adagene’s Cross-border Deals

Case:Open Innovation: Global Cooperation Exploration of Huadong Medicine

Case：Strategic Cooperation: MNC Trasaction Practice Sharing

Master Class:Global Licensing and Cooperative Trasaction of Pharmaceutical Companies

（向下滑动查看更多）

部分参会企业代表

Part Attending Companies

历届会议精彩瞬间

Wonderful Moment

(点击图片，回顾《圆满落幕 |2021亚太生物医药合作峰会》精彩瞬间！)

（扫码了解信息，快速注册报名）

【媒体合作/咨询参会/赞助合作】

Aili LI 李先生
Tel: (86 21) 6095 7201/13849919680
E-mail: aili.li@shine-consultant.com

峰会 | 守正创新、扬帆“出海” 20+路演席位火热征集，80+众多医药领袖与您共聚杭州！2023 APAC亚太生物医药合作峰会